Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
What is the purpose of this trial?
This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).
- 18 Years - 90 Years
- Celgene Corporation
- March 2012
- Last Updated:
- October 22, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT01465230